HomeCompareFTCHF vs JNJ

FTCHF vs JNJ: Dividend Comparison 2026

FTCHF yields 666666.67% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FTCHF wins by $8.275235618773884e+34M in total portfolio value
10 years
FTCHF
FTCHF
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275235618773884e+34M
Annual income
$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00
Full FTCHF calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — FTCHF vs JNJ

📍 FTCHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFTCHFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FTCHF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FTCHF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FTCHF
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, FTCHF beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FTCHF + JNJ for your $10,000?

FTCHF: 50%JNJ: 50%
100% JNJ50/50100% FTCHF
Portfolio after 10yr
$4.137617809386942e+34M
Annual income
$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

FTCHF
Analyst Ratings
10
Buy
8
Hold
1
Sell
Consensus: Buy
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FTCHF buys
0
JNJ buys
0
No recent congressional trades found for FTCHF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFTCHFJNJ
Forward yield666666.67%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$8.275235618773884e+34M$30.5K
Annual income after 10y$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$4,749.88
Total dividends collected$8.275075881065991e+34M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: FTCHF vs JNJ ($10,000, DRIP)

YearFTCHF PortfolioFTCHF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$66,677,367$66,666,666.67$10,594$274.49+$66.67MFTCHF
2$415,506,651,117$415,435,306,334.37$11,294$360.69+$415506.64MFTCHF
3$2,419,908,598,386,268$2,419,464,006,269,573.00$12,133$476.91+$2419908598.37MFTCHF
4$13,171,697,643,084,456,000$13,169,108,340,884,183,000.00$13,156$635.42+$13171697643084.44MFTCHF
5$67,004,927,492,790,120,000,000$66,990,833,776,312,020,000,000.00$14,432$854.61+$67004927492790120.00MFTCHF
6$318,562,277,003,514,840,000,000,000$318,490,581,731,097,560,000,000,000.00$16,056$1,162.76+$318562277003514871808.00MFTCHF
7$1,415,484,168,853,553,000,000,000,000,000$1,415,143,307,217,159,200,000,000,000,000.00$18,175$1,604.53+$1.415484168853553e+24MFTCHF
8$5,878,130,573,362,507,000,000,000,000,000,000$5,876,616,005,301,833,000,000,000,000,000,000.00$21,009$2,252.68+$5.878130573362507e+27MFTCHF
9$22,813,793,009,840,743,000,000,000,000,000,000,000$22,807,503,410,127,248,000,000,000,000,000,000,000.00$24,911$3,229.73+$2.2813793009840744e+31MFTCHF
10$82,752,356,187,738,840,000,000,000,000,000,000,000,000$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$30,458$4,749.88+$8.275235618773884e+34MFTCHF

FTCHF vs JNJ: Complete Analysis 2026

FTCHFStock

Farfetch Limited, together with its subsidiaries, operates a platform for the luxury fashion industry in the United States, the United Kingdom, and internationally. It operates through three segments: Digital Platform, Brand Platform, and In-Store. The company operates The Farfetch Marketplace, a global digital luxury fashion marketplace that connects consumers from approximately 190 countries and territories with merchandise from sellers, including brands, boutiques and department stores; New Guards, a platform that designs, manufactures, and distributes luxury fashion brands; Browns, a fashion and luxury goods retailer; Stadium Goods, a premium sneaker and streetwear marketplace and retailer; and VioletGrey.com, Luxclusif, Farfetch Future Retail, and other online sales channel. It also offers Farfetch Platform Solutions comprising building and operation of e-commerce and technology solutions for luxury brands and retailers; and ancillary services, including digital marketing, production, and customer services. In addition, the company operates Browns, Stadium Goods, Violet Grey, Off-White, Palm Angels, Ambush, and other brand stores; and Farfetch app. Further, the company engages in the web design, build, development, and retail distribution for retailers and brands. Farfetch Limited was founded in 2007 and is headquartered in London, the United Kingdom.

Full FTCHF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this FTCHF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FTCHF vs SCHDFTCHF vs JEPIFTCHF vs OFTCHF vs KOFTCHF vs MAINFTCHF vs ABBVFTCHF vs MRKFTCHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.